SCHEMBL599704

SCHEMBL599704

CC(O)Oc1ccc(C(=O)C(C)(C)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 2/20 0.49
KMT2A Q03164 2/20 0.46
NR1H4 Q96RI1 1/20 0.38
MLYCD O95822 1/20 0.38
ELANE P08246 4/20 0.37
MEN1 O00255 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
PARP1 P09874 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
PARP4 Q9UKK3 1/20 0.36
POLB P06746 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007396 0.87 PARP10 (0.50) PARP10KMT2ANR1H4MLYCDELANE
SCHEMBL402379 0.87 KMT2A (0.61) PARP10KMT2ANR1H4MEN1POLB
SCHEMBL18628868 0.81 KMT2A (0.39) PARP10KMT2ANR1H4ELANEPOLB
SCHEMBL13850448 0.80 KMT2A (0.41) PARP10KMT2ANR1H4MLYCDELANE
SCHEMBL9421824 0.79 KMT2A (0.44) PARP10KMT2ANR1H4MEN1POLB
SCHEMBL195348 0.79 HPGD (0.56) PARP10KMT2AELANEPARP4MAPT
SCHEMBL10591230 0.79 ELANE (0.57) PARP10KMT2AELANEMEN1CA1
SCHEMBL305364 0.78 LMNA (0.51) POLBLMNAMAPTNPSR1GAA
SCHEMBL11298330 0.78 CA2 (0.46) MLYCDELANECA2LMNASMN1; SMN2
SCHEMBL13180698 0.78 CYP1A2 (0.40) PARP10KMT2ANR1H4MLYCDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 880 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3685231-B1 3D PRINTING WITH POLYMERIC NANOGEL PARTICLES THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORATE A COLORADO NON PROFIT (US) 2026-05-13 EP claimed
EP-4565378-B1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2026-05-06 EP claimed
US-20260048177-A1 ORGANIC SOLVENT FREE COMPOSITIONS COMPRISING PROTEIN-POLYMER CONJUGATES AND USES THEREOF REGENTIS BIOMATERIALS LTD. (IL) 2026-02-19 US claimed
US-20260015799-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2026-01-15 US claimed
US-20250276022-A1 DENTIN MATRIX PROTEIN MATERIALS AND ASSOCIATED METHODS UNIV OREGON HEALTH & SCIENCE (US) 2025-09-04 US claimed
US-20250187036-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2025-06-12 US claimed
EP-4565378-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA Sicpa Holding SA (CH) 2025-06-11 EP claimed
EP-4486515-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA Sicpa Holding SA (CH) 2025-01-08 EP claimed
US-12168072-B2 Optically-induced auto-encapsulation Prellis Biologics, Inc. (US) 2024-12-17 US claimed
US-12064346-B2 System and method for implanting and securing a bioprosthetic device to wet tissue EDWARDS LIFESCIENCES CORPORATION (US) 2024-08-20 US claimed
US-7192693-B2 Methods for photopatterning hydrogels UNIVERSITY OF WASHINGTON (US) 2007-03-20 US claimed
US-20050196702-A1 degradable crosslinking agents for forming degradable, porous, photopatterned hydrogels; for immobilizing biologically active molecules; useful in a variety of medical applications NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-09-08 US claimed
US-20050118425-A1 Microcapsules containing biomedical materials MCMASTER UNIVERSITY (CA) 2005-06-02 US claimed
US-6861205-B2 Three dimensional microstructures and method of making BATTELLE MEMORIAL INSTITUTE (US) 2005-03-01 US claimed
EP-1226183-B1 PREPARATION OF LOW RESIDUAL MONOMER CONTENT POLYMERS CYTEC TECH CORP (US) 2004-08-18 EP claimed
WO-2003094898-A2 MICROCAPSULES CONTAINING BIOMEDICAL MATERIALS MCMASTER UNIVERSITY (CA) 2003-11-20 WO claimed
US-20030148222-A1 Three dimensional microstructures and method of making BATTELLE MEMORIAL INSTITUTE 2003-08-07 US claimed
EP-1226183-A1 PREPARATION OF LOW RESIDUAL MONOMER CONTENT POLYMERS CYTEC TECHNOLOGY CORP. (US) 2002-07-31 EP claimed
US-6262141-B1 FORMING GELLED POLYMER BY POLYMERIZING MIXTURE CONTAINING ACRYLIC MONOMER AND PHOTOINITIATOR IN ABSENCE OF APPLIED ULTRAVIOLET RADIATION; COMMINUTING TO PRODUCE GEL PARTICLES; IRRADIATING WITH LIGHT TO DECOMPOSE PHOTOINITIATOR CYTEC TECHNOLOGY CORPORATION 2001-07-17 US claimed
WO-2001025289-A1 PREPARATION OF LOW RESIDUAL MONOMER CONTENT POLYMERS CYTEC TECHNOLOGY CORP. (US) 2001-04-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048177-A1 ORGANIC SOLVENT FREE COMPOSITIONS COMPRISING PROTEIN-POLYMER CONJUGATES AND USES THEREOF FGB, F12, F11 PARP10 3017/4885KMT2A 4498/4885NR1H4 3260/4885
US-20260015799-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA IK, TEX10, INCENP PARP10 795/4885KMT2A 3140/4885NR1H4 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.